We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Headquartered in San Francisco, California, McKesson Corporation (MCK - Free Report) is a global provider of healthcare supply chain management solutions, retail pharmacy, community oncology cum specialty care, and healthcare information technology.
Currently, McKesson has a Zacks Rank #3 (Hold) but that could change following its first quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: McKesson’s adjusted earnings of $2.46 per share missed the Zacks Consensus Estimate of $2.81 and decreased from $3.15 in the year-ago quarter.
Revenues: McKesson posted sales of $51.05 billion, marginally missing the Zacks Consensus Estimate for revenues of $51.17 billion. This was up from $49.73 billion last year.
Key Stats: Distribution Solutions sales increased 5% at cc, while Technology Solutions decreased 83% from the year-ago quarter.
Major Factors: Performance was affected due to lower profits owing to increased price competition in pharmacy business and weaker pharmaceutical manufacturer pricing trends in U.S. Lower profit in Technology Solutions segment was driven primarily by the contribution of the majority of the businesses to Change Healthcare JV.
McKesson expects GAAP earnings per diluted share between $7.10 to $9.00 for the fiscal year ending Mar 31, 2018. Adjusted Earnings for the same are expected in the range of $11.80 to $12.50 per diluted share.
Check back later for our full write up on this McKesson report later!
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artifical intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Misses on Earnings and Sales in Q1
Headquartered in San Francisco, California, McKesson Corporation (MCK - Free Report) is a global provider of healthcare supply chain management solutions, retail pharmacy, community oncology cum specialty care, and healthcare information technology.
Currently, McKesson has a Zacks Rank #3 (Hold) but that could change following its first quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: McKesson’s adjusted earnings of $2.46 per share missed the Zacks Consensus Estimate of $2.81 and decreased from $3.15 in the year-ago quarter.
Revenues: McKesson posted sales of $51.05 billion, marginally missing the Zacks Consensus Estimate for revenues of $51.17 billion. This was up from $49.73 billion last year.
McKesson Corporation Price and EPS Surprise
McKesson Corporation Price and EPS Surprise | McKesson Corporation Quote
Key Stats: Distribution Solutions sales increased 5% at cc, while Technology Solutions decreased 83% from the year-ago quarter.
Major Factors: Performance was affected due to lower profits owing to increased price competition in pharmacy business and weaker pharmaceutical manufacturer pricing trends in U.S. Lower profit in Technology Solutions segment was driven primarily by the contribution of the majority of the businesses to Change Healthcare JV.
McKesson expects GAAP earnings per diluted share between $7.10 to $9.00 for the fiscal year ending Mar 31, 2018. Adjusted Earnings for the same are expected in the range of $11.80 to $12.50 per diluted share.
Check back later for our full write up on this McKesson report later!
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artifical intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>